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Immunopathology and Infectious Diseases
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From the National CJD Surveillance Unit,* School of Molecular
and Clinical Medicine, University of Edinburgh, Edinburgh,
United Kingdom; Central Institute for Animal Disease Control
(CIDC)-Lelystad, † Lelystad, The Netherlands; Institute for Animal
Health, Neuropathogenesis Unit, ‡ Edinburgh, United Kingdom
Molecular typing of the abnormal form of the prion
protein (PrPSc) has come to be regarded as a powerful
tool in the investigation of the prion diseases. All evi-
dence thus far presented indicates a single PrPSc molec-
ular type in variant Creutzfeldt-Jakob disease (termed
type 2B), presumably resulting from infection with a
single strain of the agent (bovine spongiform encepha-
lopathy). Here we show for the first time that the PrPSc
that accumulates in the brain in variant Creutzfeldt-
Jakob disease also contains a minority type 1 compo-
nent. This minority type 1 PrPSc was found in all 21
cases of variant Creutzfeldt-Jakob disease tested, irre-
spective of brain region examined, and was also
present in the variant Creutzfeldt-Jakob disease tonsil.
The quantitative balance between PrPSc types was main-
tained when variant Creutzfeldt-Jakob disease was
transmitted to wild-type mice and was also found in
bovine spongiform encephalopathy cattle brain, indi-
cating that the agent rather than the host specifies their
relative representation. These results indicate that PrPSc
molecular typing is based on quantitative rather than
qualitative phenomena and point to a complex relation-
ship between prion protein biochemistry, disease phe-
notype and agent strain. (Am J Pathol 2006, 168:151–157;
DOI: 10.2353/ajpath.2006.050766)
In human prion diseases, the abnormal prion protein
(PrPSc) is thought to exist in one of two major confor-
mational states, termed type 1 and type 2, which are
recognized by differences in the extent of their N-
terminal truncation following proteolytic cleavage un-
der defined conditions. Type 1 PrPSc yields a protein-
ase K-resistant core fragment with an N-terminus at
glycine 82, and type 2 yields a core fragment with an
N-terminus at serine 97.1 The presence of either type 1
or type 2 PrPSc is a characteristic feature of the sub-
types of sporadic Creutzfeldt-Jakob disease (sCJD)
adding weight to the argument that PrPSc type, in part,
underlies disease phenotype.2,3 Although microhetero-
geneity occurs within type 1 and type 2 N-termini,1
which may be affected by the conditions of proteolytic
degradation, no condition has been found that can
convert type 1 to type 2 PrPSc.4 Recent reports show
that certain cases of sCJD contain both type 1 and 2 in
the same brain.5-8 Regional variation in PrPSc type has
subsequently been reported in iatrogenic CJD9 and in
familial CJD,10 suggesting that co-occurrence of dif-
ferent PrPSc types is perhaps the rule in CJD. In con-
trast, all of the available evidence so far has suggested
that the variant CJD (vCJD) brain contains a single
type, which has been interpreted to reflect infection
of susceptible individuals by a single defined patho-
gen, namely bovine spongiform encephalopathy
(BSE).3,6,11-13 Here we re-examine that proposition, by
using a monoclonal antibody (12B2) that recognizes an
epitope (WGQGG) found at position 89-93 of human
PrP, between the type 1 and type 2 N-termini and
which should therefore specifically detect type 1 PrPSc
in proteinase K-treated samples. We compare these
results with those found using the commonly used
monoclonal antibody 3F4, that binds the epitope
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(MKHM) found at position 109-112 of human PrP and
which recognizes both type 1 and type 2 PrPSc in
proteinase K-treated samples.1–11
Materials and Methods
Human Tissue Specimens
The human tissue specimens used were collected at
autopsy, with consent and ethical approval (Lothium Re-
search Ethics Committee/2000/4/157) for retention and
research use, from patients who received a final diagno-
sis of definite vCJD (n 21) or definite sCJD (n 7), over
the period 1995-2004 in the United Kingdom. The spec-
imens were stored at 80°C until used.
Bovine Spongiform Encephalopathy Tissue
Central nervous system tissue from a Friesian cow with
terminal BSE from the Central Veterinary Laboratory (New
Haw, UK) was obtained from Dr. R.M. Ridley (Division of
Psychiatry, Clinical Research Centre, Harrow, UK).
Novel Monoclonal Antibodies
Mouse monoclonal antibody 94B4 has been described
previously.14 Mouse monoclonal antibodies 9A2 and
12B2 were produced from PrP-knockout mice,15 gener-
ously provided by Charles Weissmann (Scripps Re-
search Institute, Jupiter, FL), by immunization with a syn-
thetic peptide corresponding to ovine PrP amino acids
89-107. Prior conjugation of the peptide to keyhole limpet
hemocyanin was as previously described.16 To detect
the linear epitope specificities of 94B4, 12B2 and 9A2,
Pepscan analysis of solid-phase synthetic peptides was
performed by Pepscan Systems BV (Lelystad, The Neth-
erlands) in an enzyme-linked immunosorbent assay-like
setup as previously described.14 This used a set of over-
lapping 15-mer peptides covering the entire amino acid
sequence of ovine PrP (GenBank accession number
AJ000739). Using the human PrP sequence numbering,
the epitope for 94B4 was determined by Pepscan anal-
ysis to be 187HTVTTTTK194. The epitope for 9A2 was
found to require the residues 99WNK101 and the epitope
for 12B2 was found to require the residues 89WGQGG93
(both numbered according to the human PrP sequence).
These sequences are conserved in the human, bovine,
and murine species analyzed in these studies. Enzyme-
linked immunosorbent assay blocking experiments using
synthetic peptides and recombinant PrP confirmed the
epitope mapping for 9A2 and 12B2. However the linear
sequence 187-194 of PrP that was found to bind mono-
clonal antibody 94B4 must represent only part of the
epitope because enzyme-linked immunosorbent assay
antibody binding to peptide or recombinant PrP could
only be partially blocked by recombinant PrP or peptide.
Sample Preparation and Western Blotting
Samples were extracted, digested with proteinase K and
analyzed by Western blotting as described previously.6 A
centrifugation step was included to concentrate the lower
levels of PrPSc found in the tonsil samples.9 Ten percent
bis-Tris NuPage gels, buffers and molecular weight mark-
ers (MagicMark; Invitrogen Life Technologies, Paisley,
UK) were used, in accordance with the manufacturer’s
instructions. The proteinase K used throughout this study
was supplied stabilized in solution at 20 mg/ml (minimum
specific activity 600 mAnson U/ml) from a single batch
manufactured by British Drug Houses, and obtained from
VWR International Ltd. (Poole, UK). The standard protein-
ase K digestion conditions were 50 g/ml at 37°C for one
hour. In some experiments samples were taken from a
digestion reaction at specific time points throughout a
three-hour digestion. In other experiments a standard
one-hour digestion reaction was carried out, but the pro-
teinase K concentration ranged from 5 to 500 g/ml. The
monoclonal antibody 3F4 was obtained from Dako (High
Wycombe, UK) and used at 50 ng/ml. The monoclonal
antibody 6H4 (Prionics AG, Schlieren, Switzerland) was
used at 100 ng/ml. The monoclonal antibodies 12B2, 9A2
and 94B4 were used at 200 ng/ml. Blotting membranes
(Hybond-P), horseradish peroxidase-conjugated anti-
mouse secondary antibody, chemiluminescent reagent
(ECL) and X-ray film (Hyperfilm) were all obtained from
Amersham Biotechnology (Bucks, UK).
Transmission to Mice
Ten percent (w/v) extracts of vCJD brain were used to
inoculate C57BL, RIII and VM mice by the intracerebral
and intraperitoneal routes as described previously.13 The
mice were sacrificed after the appearance of signs of
disease and one half of the brain was examined histolog-
ically to confirm the presence of a spongiform encepha-
lopathy and the other half stored at 20°C for biochem-
ical investigations. The transmissions were performed
under an appropriate home office project license and
had been approved by the Institute for Animal Health
(Edinburgh, UK).
Results
The Western blot profile of PrPSc in sCJD (type 1) and
vCJD (type 2B) standard brain samples detected by the
newly developed monoclonal antibodies 12B2, 9A2, and
94B4 were compared with those detected by the well-
characterized 3F4 and 6H4 antibodies (Figure 1). Anti-
bodies reacting with epitopes C-terminal to serine 97
(9A2, 3F4, 6H4, and 94B4) detected both type 1 and type
2B PrPSc. Each antibody detected the triplet pattern cor-
responding to di-, mono-, and nonglycosylated PrPSc in
both type 1 and type 2B standard samples. The fragment
sizes and glycoform ratios were as expected for type 1
and type 2B PrPSc irrespective of antibody used. In ad-
dition to these fragments, a lower molecular weight frag-
ment was also detected in the type 1 standard with the
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antibodies recognizing more C-terminal epitopes (6H4
and 94B4). In marked contrast to these antibodies, 12B2
detected the type 1 PrPSc standard but failed to detect
the PrPSc in the type 2B vCJD standard sample. These
data confirm that the monoclonal antibody 12B2 suc-
cessfully targets the epitope 89WGQGG93, which is intact
in proteinase K-digested type 1 PrPSc but which is re-
moved when type 2 PrPSc is digested with proteinase K.
Hence, antibodies such as 3F4 detect both type 1 and
type 2 PrPSc, but following proteinase K digestion the
antibody 12B2 is, in effect, type 1 specific. The situation
is summarized in diagrammatic form in Figure 2.
To determine the sensitivity with which 12B2 can de-
tect type 1 PrPSc when it exists as part of a mixture of type
1 and type 2, we mixed a dilution series of proteinase
K-treated type 1 standard with a uniform amount of pro-
teinase K-treated type 2B standard. Duplicate Western
blots were probed with 3F4 (to detect type 1 and 2) and
12B2 to detect type 1 specifically (Figure 3). Both the
20-kd (type 1) and 19-kd (type 2) nonglycosylated bands
were clearly visible when the two samples were equally
mixed. Type 1 remained visible when the ratio was in-
creased to 1:0.5 and 1:0.25, but type 1 was no longer
readily distinguishable when the ratio was increased to
1:0.125 or greater. Extending the exposure time failed to
make type 1 visible at any greater dilutions because of
the increasingly saturating signal from the nearby type 2B
nonglycosylated band (data not shown). When a dupli-
cate blot was probed with 12B2, the type 2B component
of the mixture was not detected and type 1 remained
detectable when the ratio between type 2 and type 1 is as
high as 1:0.125. Because of the absence of interfering
co-detected type 2 signal, blots probed with 12B2 can be
given extended exposures. A maximal one-hour expo-
sure of the 12B2 blot showed type 1 PrPSc to be readily
detectable even when present at two orders of magni-
tude lower than the type 2 PrPSc present in the same
mixture. These data show that 12B2 is capable of detect-
ing type 1 PrPSc specifically and that 12B2 increases the
sensitivity of detecting type 1 PrPSc such that it may be
detected when it comprises less than 1% of the material
present in a mixture of type 1 and type 2. The possible
presence of type 1 PrPSc at previously undetectable lev-
els in samples from cases of vCJD previously classified
as type 2 was conducted using the 12B2 antibody and
extended Western blot exposure times.
Western blot analysis of PrPSc in samples of cerebral
cortex from six cases of vCJD using the monoclonal
antibody 3F4 showed three bands corresponding to di-,
mono-, and nonglycosylated forms (Figure 4). The type 2
Figure 1. The monoclonal antibody 12B2 detects type 1 but not type 2 PrPSc.
Western blot analysis of proteinase K-treated samples of cerebral cortex from
standard cases of sporadic CJD MM1 (Type 1) and variant CJD (Type 2B)
using the monoclonal antibodies 12B2, 9A2, 3F4, 6H4 and 94B4 is shown.
Molecular weight markers (Markers) indicate weights in kd.
Figure 2. Schematic diagram of the prion protein (amino acids 23 to 231)
showing the proteinase K-resistant core (filled box), the region of variable
proteinase K resistance (dashed line), and the region of uniform proteinase
K sensitivity (dotted line). The approximate positions of the two N-linked
glycosylation sites are indicated (CHO). The amino acid sequence of the
region of variable proteinase K sensitivity is shown. Superimposed on to this
is the position of major (large arrows) and minor (small arrows) N-termini
of proteinase K-treated type 1 (open arrows) and type 2 (filled arrows).1
The epitopes recognized by the monoclonal antibodies 3F4 and 12B2 are
marked. The resultant 3F4 Western blot profiles when sporadic CJD MM1
(Type 1) and variant CJD MM2B (Type 2) samples are digested with pro-
teinase K are shown below the sequence and the glycoforms (Di-, Mono-,
and Nonglycosylated) indicated.
Figure 3. The monoclonal antibody 12B2 detects type 1 PrPSc with sensitivity
and specificity in mixtures of type 1 and type 2B PrPSc. Western blot analysis
of serially diluted proteinase K-treated sCJD brain homogenate mixed with a
constant amount of proteinase K-treated variant CJD brain homogenate is
shown. The type 1 sCJD: type 2B vCJD ratio is shown for each lane. Duplicate
blots were probed with 3F4, which detects both type 1 and type 2 PrPSc, and
with 12B2, which detects type 1. The blot probed with 12B2 was given a
short exposure (12B2), comparable with that for the 3F4 blot, and maximal
exposure (12B2 (M)). Both blots included samples of cerebral cortex from a
case of sporadic CJD MM1 alone (Type 1) and molecular weight markers
(Markers) indicate weights in kd.
Type 1 PrPSc in Variant Creutzfeldt-Jakob Disease 153
AJP January 2006, Vol. 168, No. 1
nonglycosylated band in vCJD was clearly distinct from
the more slowly migrating nonglycosylated band found in
a typical case of sCJD (type 1), which migrated with the
20-kd molecular weight marker. When a duplicate blot
was probed with 12B2, the type 2 band was undetectable
but a band was seen that is indistinguishable in mobility
from the type 1 seen in the case of sCJD (Figure 4). The
signal found in the vCJD brain using the 12B2 therefore
had both the immunological and size characteristics ex-
pected of genuine type 1 PrPSc. The glycoform ratio of the
type 1 PrPSc found in vCJD closely resembled the glyco-
form signature of vCJD type 2 PrPSc, with a predomi-
nance of the di-glycosylated band. The abundance of the
type 1 PrPSc detected by 12B2 varied between vCJD
cases and was independent of the abundance of the type
2 PrPSc detected by 3F4. We examined cerebral cortex
from 21 cases of vCJD, and in each sample we were able
to detect type 1 PrPSc using 12B2. Sampling of 17 differ-
ent regions of a single case of vCJD using the protocol
described previously6 showed that the presence of type
1 PrPSc is not restricted to the cerebral cortex but is a
feature of all regions where type 2 PrPSc is detectable by
3F4 (Figure 5).
One possible explanation for the presence of type 1
PrPSc in these samples is that it represents incompletely
truncated type 2 PrPSc. We addressed this issue by per-
forming a proteinase K-digestion time-course experiment
(Figure 6). When probed with 3F4 the amount of PrP
signal did not decline dramatically during the three-hour
digestion, but minor increases in mobility were seen. A
shorter exposure showed this progressive increase in
mobility more clearly. In contrast there was a rapid initial
decline in the signal detected with 12B2, which pla-
teaued between 30 and 60 minutes and then remained
constant over the next two hours. Semiquantitative den-
sitometric analysis (data not shown) indicated that 60%
of the starting PrP was stably resistant to digestion and
detectable by 3F4. In contrast, the 12B2 detectable pro-
teinase K-resistant PrP was less than 10% of the starting
material. The type 1 PrPSc found in the vCJD brain re-
sisted conversion to type 2 even at proteinase K concen-
trations ten times higher (0.5 mg/ml) than the standard
assay conditions (data not shown). These two experi-
ments indicate that the type 1 PrPSc found in the vCJD
brain is not a degradative intermediate, but rather that it
results from a subpopulation of genuine type 1 PrPSc that
is consistently present in the vCJD brain samples.
To test whether this phenomenon was tissue specific,
we examined the lower levels of PrPSc that accumulated
in the vCJD tonsil. Autopsy samples of tonsil from two
cases of vCJD were tested, and both showed proteinase
K-resistant PrP that was detectable by 12B2 and had a
Figure 4. Type 1 PrPSc is detectable in the vCJD brain. Western blot analysis
of PrPSc in the cerebral cortex from six cases of vCJD is shown. Brain
homogenates were subjected to proteinase K digestion and duplicate blots
were probed with 3F4, which detects both type 1 and type 2 PrPSc, and with
12B2, which detects type 1. Both blots included samples of cerebral cortex
from a case of sporadic CJD MM1 (Type 1) and molecular weight markers
(Markers) indicate weights in kd.
Figure 5. Type 1 PrPSc is found throughout the vCJD brain. Western blot analysis of PrPSc in 17 defined brain regions of a single case of vCJD is shown. Brain
homogenates were subjected to proteinase K digestion and duplicate blots were probed with 3F4, which detects both type 1 and type 2 PrPSc, and with 12B2,
which detects type 1. Both blots included samples of cerebral cortex from a case of sporadic CJD MM1 (Type 1) and molecular weight markers (Markers) indicate
weights in kd.
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lower mobility than the band detected by 3F4 (Figure 7).
To test whether this mixture of mobility types was a fea-
ture of the agent (BSE) or the host (humans), we trans-
mitted vCJD to wild-type mice (C57BL, VM and RIII in-
bred lines) and examined the PrPSc that accumulated in
the brain. We also examined brain material from a cow
with BSE. Neither bovine nor murine PrP contained the
3F4 epitope, so we used the 6H4 antibody. Individual
C57BL mice from successful transmissions from three
different cases of vCJD all showed a band detectable by
12B2 with a lower mobility than that detected by 6H4. An
example is shown in Figure 7. The same phenomenon
was observed in a vCJD transmission to the VM and RIII
inbred lines (data not shown). The example shown in
Figure 7 resulted from the transmission from vCJD case 5
(shown in Figure 4) to C57BL mice. BSE cow brain
showed a similar result to that seen in vCJD, with 12B2
detecting a minority component that migrated more
slowly than that detected by 6H4 (Figure 7).
Lastly we considered whether this same situation ap-
plied in cases of sporadic CJD that had hitherto been
classified as containing type 2A PrPSc only. Examples
from each of the three PRNP codon 129 genotypes (MM,
MV, VV) were examined, and each showed the presence
of type 1 PrPSc as detected by 12B2, in addition to type
2A PrPSc as detected by 3F4 (Figure 8).
Discussion
In the apparent absence of a foreign nucleic acid ge-
nome associated with the agents responsible for trans-
missible spongiform encephalopathies or prion diseases,
efforts to provide a molecular definition of agent strain
have focused on biochemical differences in the abnor-
mal, disease-associated form of the prion protein, termed
PrPSc. Differences in PrPSc conformation and glycosyla-
tion have been proposed to underlie disease phenotype
and form the biochemical basis of agent strain. This
proposal has found support in the observation that the
major phenotypic subtypes of sCJD appear to correlate
with the presence of either type 1 or type 2 PrPSc in
combination with the presence of either methionine or
valine at codon 129 of the prion protein gene.2 Similarly,
the PrPSc type associated with vCJD correlates with the
presence of type 2 PrPSc and is distinct from that found in
sCJD because of a characteristically high occupancy of
both N-linked glycosylation sites (type 2B).6,11 The
means by which such conformational difference is de-
tected is somewhat indirect; relying on the action of pro-
teases, primarily proteinase K, to degrade the normal
Figure 6. Type 1 PrPSc is a stable minority component of PrPSc from the vCJD
brain. Western blot analysis of PrP in a sample of cerebral cortex from a case
of vCJD during digestion with proteinase K is shown. Time points assayed
are indicated in minutes (T0, 5, 10, 30, 60, 120, 180). Duplicate blots were
probed with 3F4, which detects both type 1 and type 2 PrPSc, and with 12B2,
which detects type 1. The insert shows a shorter exposure of the same time
course study from a separate experiment also probed with 3F4. Both blots
included samples of cerebral cortex from a case of sporadic CJD MM1 (Type
1) and molecular weight markers (Markers) indicate weights in kd.
Figure 7. A minority type 1-like PrPSc is found in vCJD tonsil, vCJD trans-
mitted to mice and in BSE. Western blot analysis of PrPSc in a concentrated
sample of tonsil from a case of vCJD (Tonsil), in a concentrated brain sample
of a wild-type mouse (C57BL) infected with vCJD and in a sample of cattle
BSE brain (BSE) is shown. Tissue extracts were digested with proteinase K.
Duplicate blots were probed with either 3F4 or 6H4, both of which detect
type 1 and type 2 PrPSc, and with 12B2, which detects type 1. The blots
included samples of cerebral cortex from a case of sporadic CJD MM1 (Type
1) and molecular weight markers (Markers) indicate weights in kd.
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cellular form of PrP and produce a protease-resistant
core fragment of PrPSc that differs in the extent of its
N-terminal truncation according to the original
conformation.
A complication has recently arisen with the finding that
both type 1 and type 2 can co-exist in the brains of
patients with sCJD.2,5-8 More recently this same phenom-
enon has been demonstrated in patients with iatrogeni-
cally acquired and familial forms of human prion dis-
ease.9,10 The existence of this phenomenon is now
beyond doubt but its prevalence and its biological sig-
nificance remain a matter of debate.
Conventional Western blot analysis using antibodies
that detect type 1 and type 2 PrPSc has severe quantita-
tive limitations for the co-detection of type 1 and type 2
PrPSc in individual samples, suggesting that the preva-
lence of co-occurrence of the two types might be under-
estimated. We have sought to circumvent this problem by
using an antibody that is type 1-specific and applied this
to the sole remaining human prion disease where the
phenomenon of mixed PrPSc types has not yet been
shown, namely vCJD.
These results show that even in vCJD where suscep-
tible individuals have been infected supposedly by a
single strain of agent, both PrPSc types co-exist: a situa-
tion reminiscent of that seen when similarly discriminant
antibodies were used to analyze experimental BSE in
sheep.14,17 In sporadic and familial CJD, individual
brains can show a wide range of relative amounts of the
two types in samples from different regions, but where
brains have been thoroughly investigated a predominant
type is usually evident.2,6,10 This differs from this report
on vCJD, where type 1 is present in all samples investi-
gated but always as a minor component that never
reaches a level at which it is detectable without a type
1-specific antibody. It would appear that the relative bal-
ance between type 1 and type 2 is controlled within
certain limits in the vCJD brain. A minority type-1-like
band is also detected by 12B2 in vCJD tonsil, in BSE
brain and in the brains of mice experimentally infected
with vCJD, suggesting that this balance of types is agent,
rather than host or tissue, specific. Interestingly the “gly-
coform signature” of the type 2 PrPSc found in vCJD (type
2B) is also seen in the type 1 PrPSc components, sug-
gesting that it could legitimately be termed type 1B.
PrPSc isotype analysis has proven to be extremely
useful in the differential diagnosis of CJD and is likely to
continue to have a major role in the investigation of hu-
man prion diseases. However, it is clear, on the basis of
these findings, that molecular typing has quantitative lim-
itations and that any mechanistic explanation of prion
replication and the molecular basis of agent strain varia-
tion must accommodate the co-existence of multiple
prion protein conformers. Whether or not the different
conformers we describe here correlate in a simple and
direct way with agent strain remains to be determined. In
principle two interpretations present themselves: either
the two conformers can be produced by a single strain of
agent or vCJD (and, therefore, presumably BSE) results
from a mixture of strains, one of which generally predom-
inates. Evidence for the isolation in mice of more than one
strain from individual isolates of BSE has been presented
previously.18,19
One practical consequence of our findings is that the
correct interpretation of transmission studies will depend
on a full examination of the balance of molecular types
present in the inoculum used to transmit disease, in ad-
dition to a thorough analysis of the molecular types that
arise in the recipients. Another consequence relates to
the diagnostic certainty of relying on PrPSc molecular
type alone when considering the possibility of BSE infec-
tion or secondary transmission in humans who have a
genotype other than methionine at codon 129 of the
PRNP gene. In this context it is interesting to note that this
minority type 1B component resembles the type 5 PrPSc
described previously to characterize vCJD transmission
into certain humanized PRNP129VV transgenic mouse
models.12,20 This apparently abrupt change in molecular
phenotype might represent a selection process imposed
by this particular transgenic mouse model. Irrespective of
whether this proves to be the case, the results shown
here point to further complexities in the relationship be-
tween the physico-chemical properties of the prion pro-
tein, human disease phenotype, and prion agent strain.
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Figure 8. Type 1 PrPSc is a minority component in cases of sporadic CJD
MM2, MV2, and VV2. Western blot analysis of PrPSc in the cerebral cortex
from three cases of sporadic CJD (sCJD) of the subtypes MM2, MV2, and VV2
is shown. Duplicate blots of proteinase K-treated brain homogenates were
probed with 3F4 which detects type 1 and type 2 PrPSc, and with 12B2, which
detects type 1. Both blots included samples of cerebral cortex from a case of
sporadic CJD MM1 (Type 1) and molecular weight markers (Markers) indi-
cate weights in kd.
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